Abstracts tagged "Health Services Research"

Abstract Number: 0748 • ACR Convergence 2022
Mapping Long COVID-19 Patient Journeys for Rheumatic Disease Patients
Yomei Shaw¹, Beth Wallace², Hallie Chabrier³, Charlotte Cochrane³, Christina Kim³, Katherine Taylor³, Armaan Patel³, Nima Keyvan⁴, Vinayak Swaroop³, Nina Nguyen³, Sara Hustek⁵, Meriah Moore⁴, Andrew Admon⁴ and Kaleb Michaud⁶, ¹FORWARD, The National Databank for Rheumatic Diseases, Santa Fe, NM, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³University of Michigan Division of Rheumatology, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan Division of Rheumatology, Mount Clemens, MI, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: One-third of individuals who contract COVID-19 develop 'long COVID' symptoms that persist after their initial illness. Long COVID can cause fatigue, chronic pain, and…
Abstract Number: 2010 • ACR Convergence 2022
Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy
Beth Wallace¹, Bryant England², Joshua Baker³, Gary Kunkel⁴, Tawnie Braaten⁵, Jorge Rojas⁶, Alison Petro², Punyasha Roul⁷, Ted Mikuls⁸, Brian Sauer⁹ and Grant Cannon¹⁰, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah Hospitals and Clinics and VA Salt Lake City Health Care System, Salt Lake City, UT, ⁶George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁹Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT
Background/Purpose: Up to 80% of RA patients use glucocorticoids (GC) at some time in their illness. Current ACR guidelines note that difficulty tapering GC promotes…
Abstract Number: 0059 • ACR Convergence 2022
Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
Kenneth Kalunian¹, Janice Ma², Konrad Pisarczyk², Richard Leff³, Kiruthi Palaniswamy⁴ and Li Long⁴, ¹University of California San Diego, La Jolla, CA, ²Maple Health Group, LLC, New York, NY, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE), which develops in about one-third of SLE patients within…
Abstract Number: 0103 • ACR Convergence 2022
Retention in Rheumatology Care and Receipt of Lupus-Specific Serologic Testing Among Young Adults with Systemic Lupus Erythematosus: A Medicare Cohort Study
Maria Schletzbaum¹, W. Ryan Powell², Shivani Garg³, Joseph A. Kramer⁴, Brad C. Astor⁵, Andrea Gilmore-Bykovskyi⁶, Amy J. Kind⁷ and Christie Bartels⁸, ¹University of Wisconsin School of Medicine and Public Health, Department of Population Health Sciences, Middleton, WI, ²University of Wisconsin School of Medicine and Public Health, Center for Health Disparities Research, Thousand Oaks, CA, ³University of Madison, School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Department of Medicine & Center for Health Disparities Research,, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Department of Medicine, Nephrology Division and Department of Population Sciences, Madison, WI, ⁶University of Wisconsin School of Medicine and Public Health, Department of Emergency Medicine; and the Center for Health Disparities Research, Madison, WI, ⁷University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division & Center for Health Disparities Research, Madison, WI, ⁸University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: SLE is a leading cause of mortality in young adults, particularly in those identifying as Black or Hispanic or who are socioeconomically disadvantaged. These…
Abstract Number: 0861 • ACR Convergence 2022
Incidence of Juvenile Idiopathic Arthritis During the COVID-19 Pandemic: An Analysis of National United States Administrative Claims Data
Daniel Horton¹, Amanda Neikirk², Yiling Yang², Cecilia Huang³, Stephen Crystal⁴, amy davidow⁵, Kevin Haynes⁶, Tobias Gerhard⁷, Carlos Rose⁸, Brian Strom⁹ and Lauren Parlett², ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²HealthCore, Wilmington, DE, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, ⁴Rutgers Center for Health Services Research, New Brunswick, NJ, ⁵New York University, New York, NY, ⁶Johnson & Johnson, Titusville, NJ, ⁷Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, ⁸Nemours, Chadds Ford, PA, ⁹Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: Limited information exists on how rates of diagnosis of rheumatic diseases have changed during the COVID-19 pandemic. We compared rates of JIA diagnosis before…
Abstract Number: 2197 • ACR Convergence 2022
Unmet Need in Systemic Lupus Erythematosus (SLE) Therapy: High Corticosteroid Use and Poor Adherence and Persistence to SLE Treatments in the US
Prajakta Masurkar¹, Jennifer Reckleff², Nicole Princic³, Brendan Limone⁴, Hana Schwartz⁴, Elaine Karis⁵, Eric Zollars⁶, Bradley Stolshek⁵ and Karen Costenbader⁷, ¹Amgen, Wylie, TX, ²Amgen, Westlake Village, CA, ³IBM Watson Health, Reading, MA, ⁴IBM Watson Health, Bethesda, MD, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Amgen, Newbury Park, CA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Poor treatment adherence and persistence is an ongoing problem among SLE patients due to complex regimens and may lead to frequent use of high-dose…
Abstract Number: 0063 • ACR Convergence 2022
Implementability of a SLE Medication Adherence Intervention
Kai Sun¹, Nneka Molokwu², Amy Corneli¹, Kathryn Pollak¹, Alexandria Bennion², Jennifer L Rogers³, Rebecca Sadun², Lisa Criscione-Schreiber¹, Jayanth Doss², Amanda Eudy⁴, Hayden Bosworth¹ and Megan Clowse², ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University School of Medicine, Division of Rheumatology & Immunology, Durham, NC, ⁴Duke University, Raleigh, NC
Background/Purpose: Medication nonadherence in SLE is common and negatively impacts patient outcomes. Yet, little is known about how to improve medication adherence in patients with…
Abstract Number: 0104 • ACR Convergence 2022
Gender Representation of the Editors and Editorial Boards of the Top 45 Rheumatology-Focused Journals
Aldo Barajas-Ochoa¹, Amaranta ManriquedeLara², Alfonso Gastelum-Strozzi³, Ingris Pelaez-Ballestas⁴, Antonio Cisneros-Barrios⁵, Manuel Ramirez-Trejo⁵, Paloma Gradilla-Magaña⁵ and Cesar Ramos-Remus⁶, ¹Rutgers New Jersey Medical School., Richmond, VA, ²Hospital General de México "Dr. Eduardo Liceaga,", Ciudad de México, Mexico, ³Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Hospital General de México "Dr. Eduardo Liceaga", Ciudad de México, Mexico, ⁵Universidad de Guadalajara, Guadalajara, Mexico, ⁶Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico
Background/Purpose: The assessment of the frequency distribution of females and males is occurring in different academic areas. Academic publishing is not exempt from potential structural…
Abstract Number: 0862 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: An Analysis of National United States Administrative Claims Data
Daniel Horton¹, Yiling Yang², Amanda Neikirk², Cecilia Huang³, Stephen Crystal⁴, amy davidow⁵, Kevin Haynes⁶, Tobias Gerhard⁷, Carlos Rose⁸, Brian Strom⁹ and Lauren Parlett², ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²HealthCore, Wilmington, DE, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, ⁴Rutgers Center for Health Services Research, New Brunswick, NJ, ⁵New York University, New York, NY, ⁶Johnson & Johnson, Titusville, NJ, ⁷Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, ⁸Nemours, Chadds Ford, PA, ⁹Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: Limited information exists on COVID-19 pandemic-related changes in the management of rheumatic diseases in adults or children, besides what patients and families have reported.…
Abstract Number: 2198 • ACR Convergence 2022
How Did a Mandatory Switching Policy for Biosimilars in Canada Impact Uptake and Spending?
Alison McClean¹, Nick Bansback¹, Lucy Cheng¹, Fiona Clemont², Mina Tadrous³, Mark Harrison¹ and Mike Law¹, ¹University of British Columbia, Vancouver, BC, Canada, ²University of Calgary, Calgary, AB, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Uptake of biosimilars has been suboptimal in North America. In 2019, British Columbia (BC) became the first jurisdiction in North America to require patients…
Abstract Number: 0066 • ACR Convergence 2022
Identifying Childhood-Onset Systemic Lupus Erythematosus, Lupus Nephritis, and End-Stage Kidney Disease Definitions Within an Administrative Claims Database
Emily Smitherman¹, Rouba Chahine¹, Aimee Hersh² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Data is lacking regarding modern real-world practices and disease outcomes of individuals with childhood-onset systemic lupus erythematosus (cSLE) and lupus nephritis, especially across multiple…
Abstract Number: 0118 • ACR Convergence 2022
Sex-Based Variations in Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions
Cheryl Barnabe¹, Patrick McLane², Nadia Luca¹, Katie Lin¹, Kelsey Chomistek¹, Meghan Elliott¹, Shanon McQuitty³, Eileen Davidson³, Clare Hildebrandt⁴, Steven Katz², Brian Holroyd² and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Patient and Family Advisors, Alberta Health Services, Calgary, AB, Canada
Background/Purpose: High quality ambulatory care provision should mitigate avoidable emergency department (ED) visits by persons with inflammatory arthritis (IA) conditions and address the unique realities…
Abstract Number: 1224 • ACR Convergence 2022
‘No Route Map’: The Complex Healthcare Journeys of People with Fibromyalgia – a Record Linkage Study in the UK
Rosemary Hollick, Ka-Kin Lam, Marcus Beasley, Gareth Jones, Corri Black and Gary Macfarlane, University of Aberdeen, Aberdeen, Scotland, United Kingdom
Background/Purpose: Healthcare services for persons with fibromyalgia (FM) lack co-ordination. Patients describe feeling 'invisible' within healthcare systems and often report poor experiences of care, particularly…
Abstract Number: 0067 • ACR Convergence 2022
Cost Per Responder in RA Patients Failing First Line Treatment
Manuel Cardozo, Pharmalab PHL, Huixquilucan, Mexico
Background/Purpose: The Colombian healthcare system is under economic pressure like many other systems in the world. In that sense, treatment choice involves cost in addition…
Abstract Number: 0119 • ACR Convergence 2022
Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions Varies by Geographic Location of Residence
Cheryl Barnabe¹, Patrick McLane², Nadia Luca¹, Kelsey Chomistek¹, Meghan Elliott¹, Shanon McQuitty³, Steven Katz², Eileen Davidson³, Clare Hildebrandt⁴, Katie Lin¹, Brian Holroyd² and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Patient and Family Advisors, Alberta Health Services, Calgary, AB, Canada
Background/Purpose: Rheumatology services in Canada are largely restricted to urban centres, resulting in significant access difficulties for residents of rural and remote locations. As a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].